The Global Corporate Development (GCoD) has recently opened new offices in Boston. The offices are located on the thirteenth floor of 10 Post Office Square, in the heart of Boston's financial district. This new location will allow direct contact with emerging biotech companies and the digital health…
Last week Chiesi hosted a digital safari workshop, organized within the company's Digital Transformation program. The workshop was led by David Orban, investor, entrepreneur, author, blogger, keynote speaker, and thought leader of the global technology landscape. He is also Professor at Singularity…
-
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein Protalix to receive $25 million upfront payment in consideration for and as reimbursement of the past costs sustained by Protalix, an additional up to $25 million in…
Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc Parma (Italy) – June 23, 2017 – Chiesi…
Chiesi is Top Employer Italy for the ninth consecutive year and Top Employer Europe for the fifth consecutive year, confirming to be among the entrepreneurial excellence for the working conditions of its employees. It is the independent research of the Top Employers Institute to certify it, which…
Chiesi receives today the Certificate Top Employers Europe for the fourth year in a row. The prize is assigned only to those organisations that create optimal employee conditions, upon evaluation of the HR strategies and policies. The CRF Institute uses a proprietary method based on the HR Best…
Alberto, Paolo and Andrea Chiesi are the National winners of the EY “ L’Imprenditore dell’Anno 2015” Award. The prestigious recognition, promoted by EY-Ernst & Young and sponsored by Azimut Wealth Management, is now at its 19 th edition. The Award is dedicated to entrepreneurs, that for at least…
Chiesi Farmaceutici has been awarded with the "Special Mention fro innovation" for Holoclar, during the ceremony of the Galeno Award, a prize promoting the most important progresses in the pharmaceutical research. The Galeno Award is considered today the Nobel prize in the Pharmaceutical area and…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
